home / stock / dmttf / dmttf news

DMTTF News and Press, Small Pharma From 01/25/23

Stock Information
Company Name: Small Pharma
Stock Symbol: DMTTF
Market: OTC
Website: smallpharma.com
Menu
DMTTF DMTTF Quote DMTTF Short DMTTF News DMTTF Articles DMTTF Message Board
Get DMTTF Alerts

News, Short Squeeze, Breakout and More Instantly...
DMTTF - Small Pharma Reports Fiscal Third Quarter 2023 Highlights

Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the ...
DMTTF - Small Pharma's psychedelic drug helps reduce depression symptoms in mid-stage study

Small Pharma's ( OTCQB:DMTTF ) psychedelic drug SPL026, with supportive therapy, met the main goal of showing reduction in depression symptoms in phase 2a trial. The two-staged Phase 2a study included evaluated a single dose of SPL026 (intravenous N,N-Dimethyltryptamine (DMT)) with s...

DMTTF - Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

First placebo-controlled efficacy study completed to date exploring a short-duration psychedelic for depression demonstrates rapid and durable response Primary endpoint met with a statistically significant -7.4 point difference between SPL026 (21.5mg) and placebo at two-weeks post-dose ...

DMTTF - Small Pharma To Announce Results of SPL026 Phase IIa Trial for Major Depressive Disorder and Host Conference Call on Wednesday, January 25

LONDON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it ...
DMTTF - First Patient Dosed in Small Pharma's Phase I Study Exploring Intramuscular Administration of SPL026

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the fi...

DMTTF - Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures New Intellectual Property

Last patient last visit complete in SPL026 Phase IIa clinical trial with topline results expected early in Q1 European patent granted for synthetic manufacturing process of key pipeline candidates LONDON, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB...

DMTTF - First Patient Dosed in Small Pharma's Drug Interaction Study

LONDON, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today confirms that the fi...
DMTTF - Small Pharma To Support University College London Research Project on Neuroplasticity

LONDON, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it wi...

DMTTF - Small Pharma to Participate in Upcoming Canaccord Genuity Investor Symposium

LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announce tha...

DMTTF - Small Pharma to Participate in November Investor and Healthcare Conferences

LONDON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, is pleased to announ...
Previous 10 Next 10